Moscow [Russia], September 13 Morning India: Russian Direct Investment Fund (RDIF) CEO Kirill Dmitriev on Saturday said that temporary suspension of AstraZeneca COVID-19 vaccine candidate trials clearly showed the “fallacy of the approach” when countries “exclusively rely on novel and untested platforms” while choosing a vaccine for widespread use.
Amid question of full indemnification by some pharma companies from any risks from their vaccines by purchasing countries, Dmitriev clarified that Russia will not follow such approach as it has demonstrated the safety and efficiency of its human adenoviral vector platform, including its Sputnik V vaccine.
Extolling the benefits of the ‘Sputnik-V’ vaccine, he said that as the vaccine was based on ‘ human adenoviral vectors’, it was proven to be ‘safe and effective’.
Comments are closed.